Effectiveness of Convalescent Immune Plasma Therapy in Severe COVID-19 Patients With Acute Respiratory Distress Syndrome
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 60
- Locations
- 2
- Primary Endpoint
- Plasma fibrinogen level
Study Overview
Brief Summary
The aim of the study is to evaluate the safety, improvement of clinical symptoms and laboratory parameters of convalescent immune plasma treatment in severe Covid-19 patients with ARDS.
Detailed Description
The aim of the study is to evaluate the safety, improvement of clinical symptoms with hypoxemia, metabolic and laboratory parameters of patients with convalescent immune plasma treatment in severe Covid-19 patients followed up in critical care unit.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 90 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Clinical diagnosis of Covid-19
Exclusion Criteria
- •Age lower than 18 Lower plasma IgA levels PaO2/FiO2 higher than 300 mmHg SpO2 higher than 90
Outcomes
Primary Outcomes
Plasma fibrinogen level
Time Frame: 7. day
Coagulopathy
Plasma procalcitonin level
Time Frame: 7. day
Infection markers
Plasma ferritin level
Time Frame: 7. day
Acute phase reactant
D-Dimer level
Time Frame: 7. day
Hypercoagulability
C-Reactive protein level
Time Frame: 7. day
Infection markers
Lymphocyte count
Time Frame: 7. day
Infection markers
Secondary Outcomes
- Fractional Inspired Oxygen Level(7. day)
- Partial Oxygen Saturation level(7. day)
- Arterial Oxygen level(7. day)